Q-omics provides the consensus-scored WFDC12 profile across patient tissues and cancer cell-line models. WFDC12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, WFDC12 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, WFDC12 RNA expression shows 7,933 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight OV, LUAD, and ESCA as cancer lineages where WFDC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC12 survival associations across molecular data types. WFDC12 RNA expression shows survival associations in the most cancer types (20), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC12 RNA expression–survival associations across cancer types. High WFDC12 expression shows unfavorable associations in OV, KIRC, UCS, SKCM, UCEC and KICH. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify OV as the clearest survival context for WFDC12 RNA expression.
This table summarizes WFDC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for WFDC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC12 shows lower tumor expression in LUAD, KICH, KIRC, BRCA and LUSC and higher tumor expression in UCEC. The LUAD box plot shows higher WFDC12 RNA expression in normal versus tumor tissue (log2 FC = −2.120, t-test p < 0.001).
This table shows molecular features associated with WFDC12 in patient tissues and cancer cell lines. In patient samples, WFDC12 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, WFDC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and OVARY.
